Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells

World Journal of Gastroenterology

Volumn 11, Issue 16, 2005, Pages 2431-2437

  Fan, Yue Zu ^a   Fu, Jin Ye ^b   Zhao, Ze Ming ^a   Chen, Cun Qiu ^a  

^a TONGJI UNIVERSITY   (China)

^b People's Hospital of Pudong District   (China)

Author keywords

Cell culture; Gallbladder neoplasm; Immunohistochemistry; Invasion; Ki 67; MMP2 and TIMP2; Norcantharidin; Oncoprotein PCNA; Proliferation

Indexed keywords

BIOTIN; CYCLINE; GELATINASE A; KI 67 ANTIGEN; MATRIGEL; NORCANTHARIDIN; STREPTAVIDIN; TETRAZOLIUM; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; COLORIMETRY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; EXPERIMENTAL DESIGN; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 18744408486     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i16.2431     Document Type: Article

References (43)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-176
2. Bartlett DL. Gallbladder cancer. Semin Surg Oncol 2000; 19: 145-155
3. Taner CB, Nagorney DM, Donobue HD. Surgical treatment of gallbladder cancer. J Gastrointest Surg 2004; 8: 83-89
4. Ito H, Matros E, Brooks DC, Osteen RT, Zinner MJ, Swanson RS, Ashley SW, Whang EE. Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointest Surg 2004; 8: 183-190
5. Muratore A, Polastri R, Capussotti L. Radical surgery for gallbladder cancer: current options. Eur J Surg Oncol 2000; 26: 438-443
6. Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98: 1689-1700
7. Kondo S, Nimura Y, Hayakawa N. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg 2000; 87: 418-422
8. Todoroki T. Chemotherapy for gallbladder carcinoma-a surgeon's perspective. Hepatogastroenterology 2000; 47: 948-955
9. Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 2004; 66: 138-142
10. Houry S, Barrier A, Huguier M. Irradiation therapy for gallbladder carcinoma: recent advances. J Hepatobiliary Pancreat Surg 2001; 8: 518-524
11. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D. Adjuvant external beam radiation therapy with concurrent chemotherapy in the treatment of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002; 52: 167-175
12. Fan YZ, Fu JY, Zhao ZM, Chun CQ. Influence of norcantharidin on proliferation and apoptosis of GBC-SD cell lines of human gallbladder carcinoma. Shanghai Yixue 2003; 26(Suppl): 1-4
13. Fan YZ, Fu JY, Zhao ZM, Chen CQ. The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism. Zhonghua Zhongliu Zazhi 2004; 26: 271-274
14. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989; 26: 147-162
15. Liu J, Gao J, Liu X. Advances in the study of Cantharidin and its derivatives. Zhongyaocai 2003; 26: 453-455
16. Williams LA, Moller W, Merisor E, Kraus W, Rosner H. In vitro anti-proliferation/ cytotoxic activity of cantharidin (Spanish-Fly) and related derivatives. West Indian Med J 2003; 52: 10-13
17. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G, Han X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 2001; 44: 2065-2068
18. McCluskey A, Ackland SP, Bowyer MC, Baldwin ML, Garner J, Walkom CC, Sakoff JA. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem 2003; 31: 68-79
19. Mack P, Ha XF, Cheng LY. Efficacy of intra-arterial norcantharidin in suppressing tumour 14C-labelled glucose oxidative metabolism in rat Morris hepatoma. HPB Surg 1996; 10: 65-72
20. Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997; 117: 93-98
21. Yi SN, Wass J, Vincent P, Iland H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991; 15: 883-886
22. Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, Lee MS, Hsiao M, Lin SK. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol 2003; 39: 19-26
23. Chen YN, Cheng CC, Chen JC, Tsauer W, Hsu SL. Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br J Pharmacol 2003; 140: 461-470
24. Liu XH, Blazsek I, Comisso M, Legras S, Marion S, Quittet P, Anjo A, Wang GS, Misset JL. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 1995; 31A: 953-963
25. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett 2004; 14: 1969-1973
26. Baba Y, Hirukawa N, Tanohira N, Sodeoka M. Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin). J Am Chem Soc 2003; 125: 9740-9749
27. Hong CY, Huang SC, Lin SK, Lee JJ, Chueh LL, Lee CH. Norcantharidin-induced post-G (2)/M apoptosis is dependent on wild-type p53 gene. Biochem Biophys Res Commun 2000; 276: 278-285
28. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF, Hsu SL. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002; 100: 158-165
29. Peng F, Wei YQ, Tian L, Yang L, Zhao X, Lu Y, Mao YQ, Kan B, Lei S, Wang GS, Jiang Y, Wang QR, Luo F, Zou LQ, Liu JY. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol 2002; 128: 223-230
30. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasm. J Pathol 1990; 162: 285-294
31. Takasaki Y, Kogure T, Takeuchi K, Kaneda K, Yano T, Hirokawa K, Hirose S, Shirai T, Hashimoto H. Reactivity of Anti-Proliferating Cell Nuclear Antigen (PCNA) Murine Monoclonal Antibodies and Human Autoantibodies to the PCNA Multiprotein Complexes Involved in Cell Proliferation. J Immunol 2001; 166: 4780-4787
32. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715
33. Aoki T, Tsukinoki K, Karakida K, Ota Y, Otsuru M, Kaneko A. Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis. Oral Oncol 2004; 40: 954-959
34. Meyer T, Hart IR. Mechanisms of tumor metastasis. Eur J Cancer 1998; 34: 214-221
35. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43(Suppl): S42-S51
36. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-433
37. Zhang JT, Fan YZ. Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and their roles in invasion and metastasis of tumor. Zhongliu 2002; 22: 161-163
38. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 1998; 77: 650-655
39. Gohji K, Fujimoto N, Fujii A, Komiyama T, Ohkawa J, Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 1996; 56: 3196-3198
40. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-6650
41. Fan YZ, Zhang JT. Significance of MMP-2/TIMP-2 in gallbladder carcinoma. J Tumor Marker Oncol 2001; 16: 339
42. Fan YZ, Zhang JT. Study on the ratio of MMP-2/TIMP-2 in patients with carcinomas of the gallbladder and their clinical value. Zhonghua Gandan Waike Zazhi 2002; 8: 630-631
43. Zhang JT, Fan YZ, Yang HC, Yang YQ. Expression and its significance of MMP-2 and TIMP-2 proteins in gallbladder carcinomas. US Chin J Lymphol Oncol 2003; 2: 36-41